Delcath Systems, Inc.
DCTHHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Delcath Systems, Inc. focuses on Medical Devices services and products. Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The $558.0M market capitalization puts DCTH squarely in small-cap range for its industry. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Market Cap
$558.0M
Beta
0.57
P/E (TTM)
1608.00
P/E (Fwd)
357.33
EPS (TTM)
$0.01
EPS (Fwd)
$0.04
ROE
0.5%
ROA
-0.9%
Cash
$95.9M
Total Debt
$2.5M
Free CF
$18.1M
52W Change
48.2%
Annual Financials
Cash vs Debt
Where DCTH stands vs its 150-day and 200-day moving averages
As of the August 31, 2026 close, DCTH finished 42.33% above its 150-day moving average ($11.48) and 47.61% above its 200-day moving average ($11.07). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DCTH overbought or oversold?
At the August 31, 2026 close, DCTH's RSI(14) was 46.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $95.9M in cash and $2.5M in debt, DCTH maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $18.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 0.5%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $2.7M (2022) to $85.2M (2025), reflecting a 3035% increase over the period.
The relatively low beta of 0.57 suggests DCTH is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. At over 50x earnings, DCTH carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. No single metric tells the full story. Reviewing DCTH's risk profile alongside its fundamentals and technical indicators provides a more complete picture.